Neuroscientific Biopharmaceuticals Ltd
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated … Read more
Neuroscientific Biopharmaceuticals Ltd (NSB) - Total Liabilities
Latest total liabilities as of June 2025: AU$149.22K AUD
Based on the latest financial reports, Neuroscientific Biopharmaceuticals Ltd (NSB) has total liabilities worth AU$149.22K AUD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neuroscientific Biopharmaceuticals Ltd - Total Liabilities Trend (2016–2025)
This chart illustrates how Neuroscientific Biopharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Neuroscientific Biopharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Neuroscientific Biopharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MegaMD Co. Ltd
KQ:133750
|
Korea | ₩17.46 Billion |
|
Whetron Electronics Co.,Ltd.
TWO:6722
|
Taiwan | NT$2.51 Billion |
|
Hilan Ltd
TA:HLAN
|
Israel | ILA1.48 Billion |
|
MGB Bhd
KLSE:7595
|
Malaysia | RM525.43 Million |
|
Omiris AG
F:HBD1
|
Germany | €1.83 Million |
|
The Ruby Mills Limited
NSE:RUBYMILLS
|
India | ₹4.75 Billion |
|
Trimitra Prawara Goldland Tbk Pt
JK:ATAP
|
Indonesia | Rp27.06 Billion |
|
Precise Biometrics AB (publ)
PINK:PRBCF
|
USA | $57.89 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Neuroscientific Biopharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 49.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 48.69 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuroscientific Biopharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuroscientific Biopharmaceuticals Ltd (2016–2025)
The table below shows the annual total liabilities of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$149.22K | +74.16% |
| 2024-06-30 | AU$85.68K | -85.66% |
| 2023-06-30 | AU$597.36K | -73.06% |
| 2022-06-30 | AU$2.22 Million | +892.65% |
| 2021-06-30 | AU$223.41K | +152.35% |
| 2020-06-30 | AU$88.53K | +41.70% |
| 2019-06-30 | AU$62.48K | -18.21% |
| 2018-06-30 | AU$76.39K | +77.02% |
| 2017-06-30 | AU$43.15K | -64.66% |
| 2016-06-30 | AU$122.12K | -- |